| __timestamp | Halozyme Therapeutics, Inc. | Iovance Biotherapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 9335772 |
| Thursday, January 1, 2015 | 40028000 | 12390000 |
| Friday, January 1, 2016 | 45853000 | 25602000 |
| Sunday, January 1, 2017 | 53816000 | 21262000 |
| Monday, January 1, 2018 | 60804000 | 28430000 |
| Tuesday, January 1, 2019 | 77252000 | 40849000 |
| Wednesday, January 1, 2020 | 45736000 | 60210000 |
| Friday, January 1, 2021 | 50323000 | 83664000 |
| Saturday, January 1, 2022 | 143526000 | 104097000 |
| Sunday, January 1, 2023 | 149182000 | 106916000 |
| Monday, January 1, 2024 | 154335000 |
Data in motion
In the ever-evolving biotech industry, operational efficiency is paramount. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc., from 2014 to 2023. Over this period, Halozyme's SG&A expenses surged by approximately 315%, peaking in 2023. Meanwhile, Iovance experienced a staggering increase of over 1,000%, reflecting its aggressive growth strategy.
This data underscores the strategic priorities of each company, with Halozyme focusing on steady growth and Iovance on rapid expansion. Investors and industry analysts can glean valuable insights into each company's operational strategies and market positioning.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: Walgreens Boots Alliance, Inc. vs Iovance Biotherapeutics, Inc.
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: ACADIA Pharmaceuticals Inc. vs Iovance Biotherapeutics, Inc.